Campath

Quote
























Anonymous said:
plus they already have the best MS marketer and trainer there (both highly respective ex-biogen employees) and soon will be getting more
Click to expand...

I suppose they meant to say respected in either case... Here's the highly respected game plan from the best highly respected ex Biogen MS marketer and trainer.
Pay docs to come ad boards, pay docs to come to weekend conferences, pay docs to be speakers, pay docs to be "consultants", pay err donate to large MS centers, repeat process as often as possible. And you know what why not it works look at Avonex. Neurologists rock!
 






Anonymous said:
I suppose they meant to say respected in either case... Here's the highly respected game plan from the best highly respected ex Biogen MS marketer and trainer.
Pay docs to come ad boards, pay docs to come to weekend conferences, pay docs to be speakers, pay docs to be "consultants", pay err donate to large MS centers, repeat process as often as possible. And you know what why not it works look at Avonex. Neurologists rock!
Click to expand...

Forgot to add pay docs for phone interviews and surveys and make up bogus studies pay docs to participate.
 




































http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095094/

"Excluding herpes virus family infections, 11 additional OIs developed in nine patients. These infections consisted of three cases of invasive pulmonary aspergillosis, two of pyomyositis and bacteremia, and one each of adenoviral pneumonia, progressive multifocal leukoencephalopathy (PML), histoplasmosis, cryptococcosis, cerebral toxoplasmosis and disseminated acanthamoebiasis. The median time to developing an OI was 169 days."

"Mortality in the alemtuzumab recipients was 37%, and seven of the 10 deaths were attributed to infection."
 






Anonymous said:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095094/

"Excluding herpes virus family infections, 11 additional OIs developed in nine patients. These infections consisted of three cases of invasive pulmonary aspergillosis, two of pyomyositis and bacteremia, and one each of adenoviral pneumonia, progressive multifocal leukoencephalopathy (PML), histoplasmosis, cryptococcosis, cerebral toxoplasmosis and disseminated acanthamoebiasis. The median time to developing an OI was 169 days."

"Mortality in the alemtuzumab recipients was 37%, and seven of the 10 deaths were attributed to infection."
Click to expand...

You are a spin doctor for sure, using quotes out of context. Your first paragraph is dealing with refractory CLL patients. By definition, these patients have a compromised immune system, and with no therapy, would eventually die of infection. Your second paragraph looks at hematopoietic stem cell transplant patients, a group of patients whose immune system has been intentionally wiped out. BTW, you forgot paste in these two sentences from the article - "In a comparator group of HSCT recipients who did not receive alemtuzumab, OI and mortality rates were similar to that of individuals who received alemtuzumab......However, the investigators have identified that in the majority of patients, there were no or only mild symptoms, and that viremia was usually easily controlled with anti-CMV therapy."

The data for Campath in MS is very strong. Your only saving grace is that Genzyme will be marketing Campath and not Bayer. If their recent track record holds true, Genzyme will screw it up royally.

Oh by the way, I had a very good conversation with a well respected neurologist in a major metro area not too long ago. His description of what he's personally seen from Tysabri goes like this, "You could equate it to 'AIDS of the Central Nervous System'. " OUCH!!
 






Anonymous said:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095094/

"Excluding herpes virus family infections, 11 additional OIs developed in nine patients. These infections consisted of three cases of invasive pulmonary aspergillosis, two of pyomyositis and bacteremia, and one each of adenoviral pneumonia, progressive multifocal leukoencephalopathy (PML), histoplasmosis, cryptococcosis, cerebral toxoplasmosis and disseminated acanthamoebiasis. The median time to developing an OI was 169 days."

"Mortality in the alemtuzumab recipients was 37%, and seven of the 10 deaths were attributed to infection."
Click to expand...

Just great!!!....looks like Tysabri and Alemtuzumab will have a contest as to how many MS patients they can try and kill.
 






Anonymous said:
You are a spin doctor for sure, using quotes out of context. Your first paragraph is dealing with refractory CLL patients. By definition, these patients have a compromised immune system, and with no therapy, would eventually die of infection. Your second paragraph looks at hematopoietic stem cell transplant patients, a group of patients whose immune system has been intentionally wiped out. BTW, you forgot paste in these two sentences from the article - "In a comparator group of HSCT recipients who did not receive alemtuzumab, OI and mortality rates were similar to that of individuals who received alemtuzumab......However, the investigators have identified that in the majority of patients, there were no or only mild symptoms, and that viremia was usually easily controlled with anti-CMV therapy."

The data for Campath in MS is very strong. Your only saving grace is that Genzyme will be marketing Campath and not Bayer. If their recent track record holds true, Genzyme will screw it up royally.

Oh by the way, I had a very good conversation with a well respected neurologist in a major metro area not too long ago. His description of what he's personally seen from Tysabri goes like this, "You could equate it to 'AIDS of the Central Nervous System'. " OUCH!!
Click to expand...

Thanks for the reply. The leukemia and transplant arena are very different than MS, as is the way a biologic will work in very different disease states. Some people will spin data to meet their sales goals and not to benefit the patient, that's the world we live in.
 












Anonymous said:
Don't forget Gilenya!
Click to expand...

Wow!! You have to be a Biogen Rep. How many .05 mg patients have died from taking Gilenya? Lets compare that to Tysabri and yes, include all PML patients. PML or death....about the same. Gilenya has been on the market over 8 months and nothing serious has been reported. How long was Killsybri out when it started taking lives?? How Biogen can be so cocky about safety data puzzles me.
 












Top Bottom
Back
Quote